How were Cogent Biosciences' earnings last quarter?

Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business earned $0.53 million during the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%.

What other stocks do shareholders of Cogent Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB) , Gran Tierra Energy (GTE) , ADMA Biologics (ADMA) , Bionano Genomics (BNGO) , Pennsylvania Real Estate Investment Trust (PEI) , CNBX Pharmaceuticals (CNBX) , KushCo (KSHB) , Novan (NOVN) , Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN) .

When did Cogent Biosciences IPO?

Cogent Biosciences (UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

NASDAQ:UMRX

Cogent Biosciences (UMRX) Stock Price, News & Analysis

→ A new way to collect income from stocks (From DTI) (Ad)

Free UMRX Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $6.39
▼
$6.58
50-Day Range: $2.35
▼
$13.01
52-Week Range: $0.29
▼
$3.72

Volume: 1.84 million shs
Average Volume: 1.22 million shs
Market Capitalization: $277.32 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Competitors Headlines Social Media

Get Cogent Biosciences alerts:

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.

Click here to learn more about the booming eHealth industry

About Cogent Biosciences Stock (NASDAQ:UMRX)

Cogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Ad Wall Street Star

This Apple-like Innovator is Revolutionizing Healthcare

Click here to learn more about the booming eHealth industry

UMRX Stock News Headlines

February 26, 2024 | markets.businessinsider.com

Analysts Conflicted on These Healthcare Names: Cogent Biosciences (COGT) and Altimmune (ALT)

February 26, 2024 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cogent Biosciences (COGT) and Moderna (MRNA)

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

February 26, 2024 | markets.businessinsider.com

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

February 15, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Cogent Biosciences Ahead of Key Data Presentation on Bezuclastinib with Strong Upside Potential

February 14, 2024 | marketwatch.com

Cogent Biosciences Stock Soars After $225M Private Placement

February 14, 2024 | msn.com

Cogent Biosciences announces oversubscribed $225M private placement

February 9, 2024 | markets.businessinsider.com

Buy Rating on Cogent Biosciences Amid Market Overreaction and Promising Drug Prospects

April 17, 2024 | Wall Street Star (Ad)

This Apple-like Innovator is Revolutionizing Healthcare

February 8, 2024 | msn.com

Citi starts Cogent Biosciences at buy, cites GI tumor drug potential

December 15, 2023 | markets.businessinsider.com

Buy Rating Reiterated for Cogent Biosciences as Bezuclastinib Shows Promise in SUMMIT Trial

December 13, 2023 | markets.businessinsider.com

Maintaining Buy on Cogent Biosciences Amid Anticipation of Differentiating Data for Bezuclastinib

December 11, 2023 | markets.businessinsider.com

Cogent Biosciences Shares Fall Despite Positive Clinical Trial Updates For Systemic Mastocytosis Treatment

December 11, 2023 | markets.businessinsider.com

Dow Surges 100 Points; Cogent Biosciences Shares Plunge

December 11, 2023 | markets.businessinsider.com

Cogent Reports Positive Data From Phase 2 APEX Trial Of Bezuclastinib In Systemic Mastocytosis

December 11, 2023 | msn.com

Cogent slumps after mid-stage data for rare disorder therapy

November 21, 2023 | markets.businessinsider.com

Potential Upside for Cogent Biosciences Due to Imminent Data Readout for Bezuclastinib and Underpriced Shares

November 14, 2023 | markets.businessinsider.com

Promising Clinical Trials and Strong Financial Position Justify Buy Rating for Cogent Biosciences

November 4, 2023 | markets.businessinsider.com

Promising Clinical Trials and Strong Financial Position Support Buy Rating for Cogent Biosciences

October 28, 2023 | markets.businessinsider.com

Promising Market Potential for Cogent Biosciences’ Bezuclastinib Spurs Buy Rating

August 30, 2023 | benzinga.com

Analyst Expectations for Cogent Biosciences's Future

August 15, 2023 | msn.com

Cogent Biosciences Is Beginning To Differentiate Its KIT Inhibitor

August 8, 2023 | markets.businessinsider.com

LifeSci Capital Remains a Buy on Cogent Biosciences (COGT)

July 11, 2023 | msn.com

Does Cogent Biosciences, Inc. (COGT) Have the Potential to Rally 78.9% as Wall Street Analysts Expect?

June 13, 2023 | marketwatch.com

Cogent Biosciences Shares Rise on Fairmount Funds Management's Stake Acquisition

June 12, 2023 | markets.businessinsider.com

9 Analysts Have This to Say About Cogent Biosciences

June 5, 2023 | markets.businessinsider.com

Cogent Biosciences (COGT) Receives a Buy from LifeSci Capital

See More Headlines

Receive UMRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cogent Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2020
Today: 4/17/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical Preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:UMRX
CUSIP: N/A
CIK: 1622229
Web: www.unumrx.com
Phone: (617) 945-5576
Fax: N/A
Employees: 72
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.04)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-31,830,000.00
Net Margins: -96.84%
Pretax Margin: N/A
Return on Equity: -87.78%
Return on Assets: -52.14%

Debt

Debt-to-Equity Ratio: 0.18
Current Ratio: 2.90
Quick Ratio: 2.90

Sales & Book Value

Annual Sales: $22.50 million
Price / Sales: 12.19
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.04 per share
Price / Book: 6.21

Miscellaneous

Outstanding Shares: 42,469,000
Free Float: N/A
Market Cap: $274.35 million
Optionable: Not Optionable
Beta: 3.93

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Andrew R. Robbins
President, Chief Executive Officer & Director
Geoffrey Hodge
Chief Technical Officer & Senior VP-Operations
John L. Green
Chief Financial & Accounting Officer
Jessica Sachs
Chief Medical Officer
Greg Motz
Head-Research

Key Competitors

View All Competitors

UMRX Stock Analysis - Frequently Asked Questions

How were Cogent Biosciences' earnings last quarter?: Cogent Biosciences, Inc. (NASDAQ:UMRX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.03. The business earned $0.53 million during the quarter. Cogent Biosciences had a negative trailing twelve-month return on equity of 87.78% and a negative net margin of 96.84%.
What other stocks do shareholders of Cogent Biosciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cogent Biosciences investors own include Matinas BioPharma (MTNB), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Bionano Genomics (BNGO), Pennsylvania Real Estate Investment Trust (PEI), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Novan (NOVN), Aeterna Zentaris (AEZS) and Zosano Pharma (ZSAN).
When did Cogent Biosciences IPO?: Cogent Biosciences (UMRX) raised $75 million in an initial public offering on Thursday, March 29th 2018. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Morgan Stanley and Cowen acted as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush Securities were co-managers.

This page (NASDAQ:UMRX) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Cogent Biosciences (UMRX) Stock Price, News & Analysis

About Cogent Biosciences Stock (NASDAQ:UMRX)

UMRX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

UMRX Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info